Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance
Christopher Darlow, Fernando Docobo-Pérez, Nicola Farrington, Adam Johnson, Laura McEntee, Jennifer Unsworth, Ana Jimenez‐Valverde, Silke Gastine, Ruwanthi Kolamunnage‐Dona, Renata M. A. de Costa, Sally Ellis, F. Franceschi, Joseph F. Standing, Mike Sharland, Michael Neely, Laura J. V. Piddock, Shampa Das, William Hope
Abstract
are the fosfomycin and amikacin MICs, respectively). Monte Carlo simulations predict that a standard fosfomycin-amikacin neonatal regimen would achieve >99% probability of pharmacodynamic success for strains with MICs below this threshold. We conclude that the combination of fosfomycin with amikacin is a viable regimen for the empirical treatment of neonatal sepsis and is suitable for further clinical assessment in a randomized controlled trial.